NATCO Pharma Limited

Equities

NATCOPHARM

INE987B01026

Pharmaceuticals

Market Closed - NSE India S.E. 09:03:23 2024-04-25 am EDT 5-day change 1st Jan Change
1,021 INR +2.26% Intraday chart for NATCO Pharma Limited +3.47% +25.86%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit MT
NATCO Pharma Limited Announces Board Appointments CI
INDIA STOCKS-Indian shares erase early gains, weighed down by IT stocks RE
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024 CI
Transcript : NATCO Pharma Limited, Q3 2024 Earnings Call, Feb 15, 2024
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024 CI
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Cellogen Therapeutics announced that it has received $2 million in funding from NATCO Pharma Limited CI
Floods Disrupt Operations of Natco Pharma's Plant in Tamil Nadu, India MT
Transcript : NATCO Pharma Limited, Q2 2024 Earnings Call, Nov 15, 2023
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend MT
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023 CI
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India MT
Transcript : NATCO Pharma Limited - Shareholder/Analyst Call
Redcliffe Hygiene Private Limited announced that it has received INR 248 million in funding from Rainmatter, Alkemi Growth Capital LLP, NATCO Pharma Limited CI
Indian Equities End Higher for Sixth Straight Day, Buoyed by Banking, Public Sector Enterprises MT
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3% MT
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit RE
Indian shares set to open flat on caution ahead of GDP data RE
Transcript : NATCO Pharma Limited, Q1 2024 Earnings Call, Aug 10, 2023
Natco Pharma to Form UK Arm MT
NATCO Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24 CI
Natco Pharma Seeks US FDA Approval for Bladder Cancer Drug MT
Chart NATCO Pharma Limited
More charts
Natco Pharma Limited is an India-based vertically integrated pharmaceutical company with focus on research and development. The Company is engaged in in the development, manufacturing and commercialization of complex pharmaceuticals that target specific therapeutic areas. It specializes in catering to niche markets and offering solutions to address complex medical needs. It owns nine manufacturing facilities across India and two research centers in Telangana. The Company’s segment includes Pharmaceuticals and Agro chemicals. Its Pharmaceuticals segment is engaged in manufacturing and selling of bulk drugs, finished dosage formulations and related services. Its Agro Chemicals is engaged in manufacturing and selling of agro chemical. It manufactures active pharmaceutical ingredients products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe, and United States of America.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
1,021 INR
Average target price
975.4 INR
Spread / Average Target
-4.48%
Consensus
  1. Stock Market
  2. Equities
  3. NATCOPHARM Stock
  4. News NATCO Pharma Limited
  5. US Court Rejects Appeal of Natco Pharma's Partner on Ibrutinib Tablets